Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2008

Solit David B, Osman Iman, Polsky David, Panageas Katherine S, Daud Adil, Goydos James S, Teitcher Jerrold, Wolchok Jedd D, Germino F Joseph, Krown Susan E, Coit Daniel, Rosen Neal, Chapman Paul B

Abstract excerpt

PURPOSE: Activation of the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase/AKT pathway seems to be critical for melanoma proliferation. Components of these pathways are client proteins of heat-shock protein 90 (hsp90), suggesting that inhibition of hsp90 coul...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Benzoquinones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Lactams, Macrocyclic

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 19088048
DOI: 10.1158/1078-0432.CCR-08-1002
PMCID: PMC2629404

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19088048-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.PMID 19088048Read ↗

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.Semantic proximity Read ↗

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.Semantic proximity Read ↗

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.Semantic proximity Read ↗

Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.Semantic proximity Read ↗

Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycinSemantic proximity Read ↗

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.Semantic proximity Read ↗

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.Semantic proximity Read ↗

Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.Semantic proximity Read ↗

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.Semantic proximity Read ↗

Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.Semantic proximity Read ↗

Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.Semantic proximity Read ↗

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.